---
title: Dexmedetomidine vs. Propofol for Cataract Surgery
nct_id: NCT00786370
overall_status: COMPLETED
phase: PHASE4
sponsor: The Cooper Health System
study_type: INTERVENTIONAL
primary_condition: Cataract
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00786370.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00786370"
ct_last_update_post_date: 2012-02-10
last_seen_at: "2026-05-12T06:18:55.713Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Dexmedetomidine vs. Propofol for Cataract Surgery

**Official Title:** Dexmedetomidine vs. Propofol for Monitored Anesthesia Care During Cataract

**NCT ID:** [NCT00786370](https://clinicaltrials.gov/study/NCT00786370)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 24
- **Lead Sponsor:** The Cooper Health System
- **Conditions:** Cataract
- **Start Date:** 2008-04
- **Completion Date:** 2010-04
- **CT.gov Last Update:** 2012-02-10

## Brief Summary

The use of dexmedetomidine in cataract surgery is still limited and to date only one study has examined anesthetic technique in this patient population. This pilot study will therefore compare the use of dexmedetomidine and propofol in subjects undergoing cataract surgery. The primary endpoint will be based on simple cardiorespiratory measures often associated with complications from sedation as well as assessment of the achieved sedation by the attending anesthesiologist and surgeon.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Normal renal function
2. No chronic use of narcotics
3. ASA PS1-3
4. Males or females age 18 or older

Exclusion Criteria:

1. Liver disease (Child Pugh classification 1-3)
2. History of chronic use of sedatives, narcotics, alcohol or illicit drugs or allergy to any the study medications
3. History of 1st and 2nd degree heart block (not paced)
4. Any patient with EF \< 30%
5. Patients with active seizure history
6. Pregnant patients (women of child bearing potential will have a preoperative pregnancy test as is standard of practice)
```

## Arms

- **Propofol** (ACTIVE_COMPARATOR)
- **Dexmedetomidine** (EXPERIMENTAL)

## Interventions

- **dexmedetomidine** (DRUG) — Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
- **Propofol** (DRUG) — continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
- **Dexemedetomidine** (DRUG) — continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.

## Primary Outcomes

- **To compare select cardiorespiratory effects of dexmedetomidine sedation to those of propofol sedation in patients undergoing cataract surgery.** _(time frame: 1 day)_

## Locations (1)

- Cooper University Hospital, Camden, New Jersey, United States

## Recent Field Changes (last 30 days)

- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.cooper university hospital|camden|new jersey|united states` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00786370.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00786370*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*